Comparing two assays for clinical genomic profiling: the devil is in the data [Letter of clarification]

Glen J Weiss
Vivek Khemka
Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ, USA

Dear editor

It has come to our attention that the second and fourth paragraph of our Authors’ reply may be misconstrued as an endorsement of the Paradigm Cancer Diagnostics (PCDx) test by Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ, USA. This was not our intention. We stand by the interpretation of the results of the original manuscript and the remainder of the content of the Authors’ reply. We welcome a more robust clinical comparison of these two platforms, as well as any other platform that may improve the clinical decision-making and outcomes for patients with advanced cancer.

Disclosure

GJW is a clinical oncology advisor to Viomics and a scientific and medical advisor to Paradigm. All authors had control of the data and information submitted for the reply to the letter to the editor. The authors report no other conflicts of interest in this communication.

Reference